GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Forward PE Ratio

Faron Pharmaceuticals Oy (LSE:FARN) Forward PE Ratio : 0.00 (As of Jun. 11, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Forward PE Ratio?

Faron Pharmaceuticals Oy's Forward PE Ratio for today is 0.00.

Faron Pharmaceuticals Oy's PE Ratio without NRI for today is 0.00.

Faron Pharmaceuticals Oy's PE Ratio for today is 0.00.


Faron Pharmaceuticals Oy Forward PE Ratio Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Forward PE Ratio Chart

Faron Pharmaceuticals Oy Annual Data
Trend
Forward PE Ratio

Faron Pharmaceuticals Oy Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Faron Pharmaceuticals Oy's Forward PE Ratio

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Forward PE Ratio falls into.



Faron Pharmaceuticals Oy Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Faron Pharmaceuticals Oy  (LSE:FARN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Faron Pharmaceuticals Oy Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines